TScan Therapeutics Inc. (TCRX), a clinical-stage biotechnology company, is set to host a virtual key opinion leader (KOL) event on December 8, 2025, at 8:00 a.m. ET. to discuss updates from its ongoing ALLOHA trial.
ALLOHA is a Phase 1 trial evaluating TSC-101 in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).
TSC-101 is an allogeneic, donor-derived T-cell therapy that targets minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
During the event, the company will be presenting two-year relapse data on initial patients from the ALLOHA Phase 1 trial and also review the unmet medical need and potential market opportunity for TSC-101 and follow-on product candidates.
According to a recent update, TSC-101 demonstrated a favorable safety profile and durable long-term persistence, with TCR-T cells detected more than two years post-infusion and a clear relationship between dose and persistence. The therapy also showed a meaningful relapse-free benefit, with 82% of patients (14/17) in the treatment arm remaining relapse-free, compared to 64% (9/14) in the control arm.
Last month, after a productive End-of-Phase 1 meeting with the FDA, the company agreed on the registrational path forward for the TSC-101 program as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
A pivotal trial for TSC-101 for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is expected to be launched in the second quarter of 2026.
TCRX closed Wednesday's trade at $1.02, up 7.12 %.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.